LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results
IPO bolsters balance sheet to $160 million in cash and cash equivalents; expected to fund operations at least into the second half of 2023
Clinical development plans on schedule in both hematological and solid tumor programs
Leadership strengthened through key management and board appointments
UTRECHT, The Netherlands and PHILADELPHIA, May 20, 2021 (GLOBE NEWSWIRE) LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in gamma-delta bispecific T cell engagers (bsTCEs) to transform cancer therapy, today reported its business update and first quarter 2021 financial results.
“We continue to make important strides across all aspects of our business as we transition to a clinical stage organization,” said Stephen Hurly, chief executive officer of LAVA Therapeutics. “With the recent additions to our leadership team and board and the proceeds from
LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results GlobeNewswire May 20, 2021 IPO bolsters balance sheet to $160 million in cash and cash equivalents; expected to fund operations at least into the second half of 2023 UTRECHT, The Netherlands and PHILADELPHIA, May 20, 2021 (GLOBE NEWSWIRE) LAVA Therapeutics.
LAVA Therapeutics BV: LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results
Clinical development plans on schedule in both hematological and solid tumor programs
Leadership strengthened through key management and board appointments
UTRECHT, The Netherlands and PHILADELPHIA, May 20, 2021 (GLOBE NEWSWIRE) LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in gamma-delta bispecific T cell engagers (bsTCEs) to transform cancer therapy, today reported its business update and first quarter 2021 financial results. We continue to make important strides across all aspects of our business as we transition to a clinical stage organization, said Stephen Hurly, chief executive officer of LAVA Therapeutics. With the recent additions to our leadership team and board and the proceeds from our IPO, we are well-positioned to advance our pipeline as we work toward our mission of transforming cancer therapy for patie